Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Abliva (OMX: ABLI)

Last close As at 21/11/2024

0.17

▲ −0.01 (−5.56%)

Market capitalisation

SEK195m

NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine. It has a diversified portfolio in terms of indications and employs a dual strategy: it develops a core portfolio of assets for orphan diseases and seeks to out-license proprietary products for non-orphan indications. NeuroSTAT (neurotrauma, Phase IIb ready) and KL1333 (genetic mitochondrial diseases) are the most advanced assets.

Latest Insights

View More

Healthcare | Update

Abliva — IND approved by the FDA, preparing for Ph II/III

Healthcare | Update

Abliva — KL1333 ready for pivotal Phase II/III trial

Healthcare | Update

Abliva — New strategic investor on board and CMD

Healthcare | Update

NeuroVive Pharmaceutical — Rights issue and focus on core assets
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.4) (11.9) (72.7)
Relative (0.9) (20.7) (63.8)
52 week high/low SEK0.6/SEK0.2

Financials

Edison Investment Research is terminating coverage on Abliva (ABLI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2020A 1.9 (55.0) (57.4) (23.00) N/A N/A
2021A 0.2 (117.9) (120.4) (34.44) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A